Tingley Whittemore 4

What Happened Tingley Whittemore, Chief Medical Officer of Tenaya Therapeutics (TNYA), was granted two equity awards on February 3, 2026: 48,750 restricted stock units (RSUs) and a derivative award covering 318,500 shares (an option). Both grants were reported with an acquisition price of $0.00. These are compensatory grants (not open‑market purchases or sales) that vest over time; they represent a potential 367,250 shares if fully vested/exercised.

Key Details

• Transaction date: February 3, 2026; Form 4 filed February 5, 2026 (appears timely).
• Grant amounts: 48,750 RSUs (F1) and 318,500‑share option award (derivative).
• Reported acquisition price: $0.00 for both grants.
• Vesting - RSUs (F2): 1/8 of the total vests on August 15, 2026, then 1/8 every six months thereafter until fully vested.
• Vesting - Option (F4): vests monthly — 1/48th after one month, then 1/48th each monthly anniversary until fully vested.
• Shares reflected in ownership (F3): filing notes 134,588 shares that will be issued upon RSU vesting are included in the reported beneficial ownership figure.
• Nature of transaction: Award/grant (code A) — not an immediate purchase or sale; no cash proceeds or disposition reported.

Context

• RSUs convert to actual shares when vested; options give the right to acquire shares per the plan and vesting schedule. These awards are typical executive compensation and do not indicate an immediate market trade.